Haya Therapeutics shouts ‘hiya!’ as it emerges from stealth with seed funding

  • Swiss precision medicine biotech Haya Therapeutics is coming out of stealth today with nearly $20 million, or CHF 18 million, in seed funding to boost its anti-fibrotic therapies.  

    The preclinical startup’s seed round was led by Broadview Ventures and included participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.